TY - JOUR
T1 - Comparative aspects of the care of familial hypercholesterolemia in the ‘‘Ten Countries Study’’
AU - Pang, Jing
AU - Chan, Dick
AU - Hu, Miao
AU - Muir, Lauretta
AU - Kwok, See
AU - Charng, Min-Ji
AU - Florkowski, Christopher
AU - George, Peter
AU - Lin, Jie
AU - Loi, Do Doan
AU - Marais, A. David
AU - Nawawi, Hapizah
AU - Gonzalez-Santos, Lourdes
AU - Su, Ta-Chen
AU - Truong, Thanh Huong
AU - Santos, Raul
AU - Soran, Handrean
AU - Tomlinson, Brian
AU - Yamashita, Shizuya
AU - Ademi, Zanfina
AU - Watts, Gerald
PY - 2019
Y1 - 2019
N2 - BACKGROUND: There is a lack of information on the health care of familial hypercholesterolemia (FH).OBJECTIVE: The objective of this study was to compare the health care of FH in countries of the Asia-Pacific region and Southern Hemisphere.METHODS: A series of questionnaires were completed by key opinion leaders from selected specialist centers in 12 countries concerning aspects of the care of FH, including screening, diagnosis, risk assessment, treatment, teaching/training, and research; the United Kingdom (UK) was used as the international benchmark.RESULTS: The estimated percentage of patients diagnosed with the condition was low (overall <3%) in all countries, compared with w15% in the UK. Underdetection of FH was associated with government expenditure on health care (x= 0.667, P<.05). Opportunistic and systematic screening methods, and the Dutch Lipid Clinic Network criteria were most commonly used to detect FH; genetic testing was infrequently used. Noninvasive imaging of coronary calcium and/or carotid plaques was underutilized in risk assessment. Patients with FH were generally not adequately treated, with <30% of patients achieving guideline recommended low-density lipoprotein cholesterol targets on conventional therapies. Treatment gaps included suboptimal availability and use of lipoprotein apheresis and proprotein convertase subtilsin-kexin type 9 inhibitors. A deficit of FH registries, training programs, and publications were identified in less economically developed countries. The demonstration of cost-effectiveness for cascade screening, genetic testing, and specialized treatments were significantly associated with the availability of subsidies from the health care system (x=0.571–0.800, P < .05).CONCLUSION: We identified important gaps across the continuum of care for FH, particularly inless economically developed countries. Wider implementation of primary and pediatric care, telehealth services, patient support groups, education/training programs, research activities, and health technology assessments are needed to improve the care of patients with FH in these countries.
AB - BACKGROUND: There is a lack of information on the health care of familial hypercholesterolemia (FH).OBJECTIVE: The objective of this study was to compare the health care of FH in countries of the Asia-Pacific region and Southern Hemisphere.METHODS: A series of questionnaires were completed by key opinion leaders from selected specialist centers in 12 countries concerning aspects of the care of FH, including screening, diagnosis, risk assessment, treatment, teaching/training, and research; the United Kingdom (UK) was used as the international benchmark.RESULTS: The estimated percentage of patients diagnosed with the condition was low (overall <3%) in all countries, compared with w15% in the UK. Underdetection of FH was associated with government expenditure on health care (x= 0.667, P<.05). Opportunistic and systematic screening methods, and the Dutch Lipid Clinic Network criteria were most commonly used to detect FH; genetic testing was infrequently used. Noninvasive imaging of coronary calcium and/or carotid plaques was underutilized in risk assessment. Patients with FH were generally not adequately treated, with <30% of patients achieving guideline recommended low-density lipoprotein cholesterol targets on conventional therapies. Treatment gaps included suboptimal availability and use of lipoprotein apheresis and proprotein convertase subtilsin-kexin type 9 inhibitors. A deficit of FH registries, training programs, and publications were identified in less economically developed countries. The demonstration of cost-effectiveness for cascade screening, genetic testing, and specialized treatments were significantly associated with the availability of subsidies from the health care system (x=0.571–0.800, P < .05).CONCLUSION: We identified important gaps across the continuum of care for FH, particularly inless economically developed countries. Wider implementation of primary and pediatric care, telehealth services, patient support groups, education/training programs, research activities, and health technology assessments are needed to improve the care of patients with FH in these countries.
U2 - 10.1016/j.jacl.2019.01.009
DO - 10.1016/j.jacl.2019.01.009
M3 - Article
SN - 1933-2874
SP - 287
EP - 300
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
ER -